There are eight firms with a “buy” rating and three analysts with a “sell” rating. There is a one-year price target of $16.75, according to the report.
JPMorgan Chase & Co., reiterated the “neutral” rating with a price target at $14.67 earlier this week. Last week, Beaufort Securities reiterated the “sell” rating.
This past Monday, Smith & Nephew’s Julie Brown sold 4,227 shares on the open market at $17 per share for a total transaction reaching $71,869.19.
More articles on surgery:
5 key notes on delayed spine surgery after traumatic central cord syndrome
Power vs. manual tools for scoliosis surgery—5 key notes
5 things to know about adult spinal deformity surgical revision rates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
